Next Article in Journal
Dietary Patterns and the Risk of Prediabetes in Taiwan: A Cross-Sectional Study
Next Article in Special Issue
Effects of l-Carnitine Supplementation in Patients Receiving Hemodialysis or Peritoneal Dialysis
Previous Article in Journal
Nutrition, Microbiota and Role of Gut-Brain Axis in Subjects with Phenylketonuria (PKU): A Review
Previous Article in Special Issue
Nutritional Guideline for the Management of Mexican Patients with CKD and Hyperphosphatemia
Open AccessArticle

Antihypertensive Effects of Gynura divaricata (L.) DC in Rats with Renovascular Hypertension

1
College of Oriental Medicine and Professional Graduate School of Oriental Medicine, Wonkwang University, Iksan, Jeonbuk 54538, Korea
2
Hanbang Cardio-renal Research Center & Professional Graduate School of Oriental Medicine, Wonkwang University, Iksan, Jeonbuk 54538, Korea
3
College of Pharmacy, Wonkwang University, Iksan 54538, Korea
*
Authors to whom correspondence should be addressed.
Nutrients 2020, 12(11), 3321; https://doi.org/10.3390/nu12113321
Received: 17 September 2020 / Revised: 19 October 2020 / Accepted: 22 October 2020 / Published: 29 October 2020
(This article belongs to the Special Issue Nutrition Management for CKD (Chronic Kidney Disease))
Gynura divaricata (L.) DC (Compositae) (GD) could be found in various parts of Asia. It has been used as a traditional medicine to treat diabetes, high blood pressure, and other diseases, but its effects have not yet been scientifically confirmed. Therefore, we aimed at determining whether GD could affect renal function regulation, blood pressure, and the renin-angiotensin-aldosterone system (RAAS). Cardio-renal syndrome (CRS) is a disease caused by the interaction between the kidney and the cardiovascular system, where the acute or chronic dysfunction in one organ might induce acute or chronic dysfunction of the other. This study investigated whether GD could improve cardio-renal mutual in CRS type 4 model animals, two-kidney one-clip (2K1C) renal hypertensive rats. The experiments were performed on the following six experimental groups: control rats (CONT); 2K1C rats (negative control); OMT (Olmetec, 10 mg/kg/day)-treated 2K1C rats (positive control); and 2K1C rats treated with GD extracts in three different doses (50, 100, and 200 mg/kg/day) for three weeks by oral intake. Each group consisted of 10 rats. We measured the systolic blood pressure weekly using the tail-cuff method. Urine was also individually collected from the metabolic cage to investigate the effect of GD on the kidney function, monitoring urine volume, electrolyte, osmotic pressure, and creatinine levels from the collected urine. We observed that kidney weight and urine volume, which would both display typically increased values in non-treated 2K1C animals, significantly decreased following the GD treatment (###p < 0.001 vs. 2K1C). Osmolality and electrolytes were measured in the urine to determine how renal excretory function, which is reduced in 2K1C rats, could be affected. We found that the GD treatment improved renal excretory function. Moreover, using periodic acid-Schiff staining, we confirmed that the GD treatment significantly reduced fibrosis, which is typically increased in 2K1C rats. Thus, we confirmed that the GD treatment improved kidney function in 2K1C rats. Meanwhile, we conducted blood pressure and vascular relaxation studies to determine if the GD treatment could improve cardiovascular function in 2K1C rats. The heart weight percentages of the left atrium and ventricle were significantly lower in GD-treated 2K1C rats than in non-treated 2K1C rats. These results showed that GD treatment reduced cardiac hypertrophy in 2K1C rats. Furthermore, the acetylcholine-, sodium nitroprusside-, and atrial natriuretic peptide-mediated reduction of vasodilation in 2K1C rat aortic rings was also ameliorated by GD treatment (GD 200 mg/kg/day; p < 0.01, p < 0.05, and p < 0.05 vs. 2K1C for vasodilation percentage in case of each compound). The mRNA expression in the 2K1C rat heart tissue showed that the GD treatment reduced brain-type natriuretic peptide and troponin T levels (p < 0.001 and p < 0.001 vs. 2K1C). In conclusion, this study showed that GD improved the cardiovascular and renal dysfunction observed in an innovative hypertension model, highlighting the potential of GD as a therapeutic agent for hypertension. These findings indicate that GD shows beneficial effects against high blood pressure by modulating the RAAS in the cardio-renal syndrome. Thus, it should be considered an effective traditional medicine in hypertension treatment. View Full-Text
Keywords: renovascular hypertension; Gynura divaricata (L.) DC; renin-angiotensin-aldosterone system (RAAS); cardio-renal syndrome renovascular hypertension; Gynura divaricata (L.) DC; renin-angiotensin-aldosterone system (RAAS); cardio-renal syndrome
Show Figures

Graphical abstract

MDPI and ACS Style

Hong, M.H.; Jin, X.J.; Yoon, J.J.; Lee, Y.J.; Oh, H.C.; Lee, H.S.; Kim, H.Y.; Kang, D.G. Antihypertensive Effects of Gynura divaricata (L.) DC in Rats with Renovascular Hypertension. Nutrients 2020, 12, 3321. https://doi.org/10.3390/nu12113321

AMA Style

Hong MH, Jin XJ, Yoon JJ, Lee YJ, Oh HC, Lee HS, Kim HY, Kang DG. Antihypertensive Effects of Gynura divaricata (L.) DC in Rats with Renovascular Hypertension. Nutrients. 2020; 12(11):3321. https://doi.org/10.3390/nu12113321

Chicago/Turabian Style

Hong, Mi H.; Jin, Xian J.; Yoon, Jung J.; Lee, Yun J.; Oh, Hyun C.; Lee, Ho S.; Kim, Hye Y.; Kang, Dae G. 2020. "Antihypertensive Effects of Gynura divaricata (L.) DC in Rats with Renovascular Hypertension" Nutrients 12, no. 11: 3321. https://doi.org/10.3390/nu12113321

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop